Japan's Taiho Looks At Partnerships To Jumpstart Gastric Cancer Drug Global Expansion
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Taiho Pharmaceutical Nov. 19 announced the European Medicines Agency accepted for review the company's marketing application for the gastric cancer drug S-1
You may also be interested in...
Otsuka Looks To IPO To Fund Overseas Expansion
Otsuka Holdings, the parent company of Japan's fifth-largest pharmaceutical company Otsuka Pharmaceutical, could go public on the Tokyo Stock Exchange within the year
Otsuka Looks To IPO To Fund Overseas Expansion
Otsuka Holdings, the parent company of Japan's fifth-largest pharmaceutical company Otsuka Pharmaceutical, could go public on the Tokyo Stock Exchange within the year
Banyu To Sell Facility To Taiho, Move All Research To U.S.
Japan's Banyu Pharmaceutical plans to sell its research facility to Taiho Pharmaceutical, with the deal to be completed by the end of August. Banyu, a subsidiary of U.S.-based Merck, is moving its research work to the United States and assigning its employees at the Japanese facility to other divisions. The Banyu change is part of a global restructuring by Merck. For Taiho, the facility is to serve as its base for developing the cancer drugs in which it specializes. (Click here for more - a subscription may be required